143 related articles for article (PubMed ID: 2759546)
41. Lack of effect of asymmetrical dosage timing of isosorbide-5-mononitrate on nitrate tolerance during long-term administration.
Hughes LO; DasGupta P; Jain D; Lahiri A; Raftery EB
Eur J Clin Pharmacol; 1989; 36(2):139-44. PubMed ID: 2498105
[TBL] [Abstract][Full Text] [Related]
42. Renal effects of acute isosorbide-5-mononitrate administration in cirrhosis.
Salmerón JM; Ruiz del Arbol L; Ginès A; García-Pagán JC; Ginès P; Feu F; Claria J; Rivera F; Bosch J; Arroyo V
Hepatology; 1993 May; 17(5):800-6. PubMed ID: 8491447
[TBL] [Abstract][Full Text] [Related]
43. Comparison between portal vein pressure and wedged hepatic vein pressure in hepatitis B-related cirrhosis.
Lin HC; Tsai YT; Lee FY; Chang TT; Wang SS; Lay CS; Lee SD; Lo KJ
J Hepatol; 1989 Nov; 9(3):326-30. PubMed ID: 2607121
[TBL] [Abstract][Full Text] [Related]
44. Mechanism of action of isosorbide-5-mononitrate in reducing portal pressure in cirrhotic patients with cirrhosis and portal hypertension.
Jenkins SA; Shields R
J Gastroenterol Hepatol; 1991; 6(1):91-3. PubMed ID: 1883984
[No Abstract] [Full Text] [Related]
45. Doppler sonography and hepatic vein catheterization in portal hypertension: assessment of agreement in evaluating severity and response to treatment.
Merkel C; Sacerdoti D; Bolognesi M; Bombonato G; Gatta A
J Hepatol; 1998 Apr; 28(4):622-30. PubMed ID: 9566831
[TBL] [Abstract][Full Text] [Related]
46. The effect of a combined treatment with propranolol and isosorbide-5-mononitrate on Doppler ultrasound parameters in patients with cirrhosis and portal hypertension.
Orban Schiopu AM; Balas BI; Diculescu M
Rom J Gastroenterol; 2005 Jun; 14(2):123-7. PubMed ID: 15990930
[TBL] [Abstract][Full Text] [Related]
47. Randomized controlled trial of oral captopril, of oral isosorbide mononitrate and of intravenous magnesium sulphate started early in acute myocardial infarction: safety and haemodynamic effects. ISIS-4 (Fourth International Study of Infarct Survival) Pilot Study Investigators.
Flather M; Pipilis A; Collins R; Budaj A; Hargreaves A; Kolettis T; Jacob A; Millane T; Fitzgerald L; Cedro K
Eur Heart J; 1994 May; 15(5):608-19. PubMed ID: 8055999
[TBL] [Abstract][Full Text] [Related]
48. Effects of isosorbide mononitrate and AII inhibition on pulse wave reflection in hypertension.
Stokes GS; Barin ES; Gilfillan KL
Hypertension; 2003 Feb; 41(2):297-301. PubMed ID: 12574098
[TBL] [Abstract][Full Text] [Related]
49. Vascular hyporeactivity persists despite increased contractility after long-term administration of isosorbide dinitrate in portal hypertensive rats.
Huang YT; Lin HC; Tsai JF; Hou MC; Lee SD; Hong CY
J Hepatol; 1998 Jun; 28(6):1037-44. PubMed ID: 9672181
[TBL] [Abstract][Full Text] [Related]
50. Hemodynamic effect of propranolol on portal hypertension in patients with HBsAg-positive cirrhosis.
Kong CW; Lay CS; Tsai YT; Lee SD; Lai KH; Lo KJ; Chiang BN
Dig Dis Sci; 1986 Dec; 31(12):1303-6. PubMed ID: 3803132
[TBL] [Abstract][Full Text] [Related]
51. Randomised trial of nadolol alone or with isosorbide mononitrate for primary prophylaxis of variceal bleeding in cirrhosis. Gruppo-Triveneto per L'ipertensione portale (GTIP).
Merkel C; Marin R; Enzo E; Donada C; Cavallarin G; Torboli P; Amodio P; Sebastianelli G; Sacerdoti D; Felder M; Mazzaro C; Beltrame P; Gatta A
Lancet; 1996 Dec 21-28; 348(9043):1677-81. PubMed ID: 8973428
[TBL] [Abstract][Full Text] [Related]
52. Effect of isosorbide dinitrate, verapamil, and labetalol on portal pressure in cirrhosis.
Freeman JG; Barton JR; Record CO
Br Med J (Clin Res Ed); 1985 Aug; 291(6495):561-2. PubMed ID: 3929873
[TBL] [Abstract][Full Text] [Related]
53. [Acute effects of isosorbide mononitrate on blood circulation and myocardial ischemia in patients with coronary atherosclerosis].
Manfroi WC; Zago AJ; Ribeiro JP; Raudales JC; Fanti L; Brum EM; Perin A; Oliveira J
Arq Bras Cardiol; 1995 Jul; 65(1):11-5. PubMed ID: 8546588
[TBL] [Abstract][Full Text] [Related]
54. Hemodynamic evaluation of octreotide in patients with hepatitis B-related cirrhosis.
Lin HC; Tsai YT; Lee FY; Lee SD; Hsia HC; Lin WJ; Lo KJ
Gastroenterology; 1992 Jul; 103(1):229-34. PubMed ID: 1612330
[TBL] [Abstract][Full Text] [Related]
55. Effects of terlipressin on systemic, hepatic and renal hemodynamics in patients with cirrhosis.
Narahara Y; Kanazawa H; Taki Y; Kimura Y; Atsukawa M; Katakura T; Kidokoro H; Harimoto H; Fukuda T; Matsushita Y; Nakatsuka K; Sakamoto C
J Gastroenterol Hepatol; 2009 Nov; 24(11):1791-7. PubMed ID: 19686420
[TBL] [Abstract][Full Text] [Related]
56. The hemodynamic effect of verapamil on portal hypertension in patients with postnecrotic cirrhosis.
Kong CW; Lay CS; Tsai YT; Yeh CL; Lai KH; Lee SD; Lo KJ; Chiang BN
Hepatology; 1986; 6(3):423-6. PubMed ID: 3710430
[TBL] [Abstract][Full Text] [Related]
57. Isosorbide-5-mononitrate in the treatment of pulmonary hypertension associated with portal hypertension.
Ribas J; Angrill J; Barberà JA; García-Pagán JC; Roca J; Bosch J; Rodriguez-Roisin R
Eur Respir J; 1999 Jan; 13(1):210-2. PubMed ID: 10836350
[TBL] [Abstract][Full Text] [Related]
58. Effects of verapamil on hepatic and systemic hemodynamics and liver function in patients with cirrhosis and portal hypertension.
Navasa M; Bosch J; Reichen J; Bru C; Mastai R; Zysset T; Silva G; Chesta J; Rodés J
Hepatology; 1988; 8(4):850-4. PubMed ID: 3391511
[TBL] [Abstract][Full Text] [Related]
59. Long-acting isosorbide mononitrate.
Prakash A; Markham A
Drugs; 1999 Jan; 57(1):93-9; discussion 100. PubMed ID: 9951954
[TBL] [Abstract][Full Text] [Related]
60. [Effect of different molecules on portal, pulmonary and systemic hemodynamics in the cirrhotic patient].
Reding P; Naeije R; Hallemans R; Mols P; Mélot C
Acta Gastroenterol Belg; 1983; 46(3-4):127-30. PubMed ID: 6140807
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
